EnterNext welcomes Mithra Pharmaceuticals to Euronext Brussels

Brussels, 30 June 2015 – EnterNext, the Euronext subsidiary designed to promote and grow the market for mid and small capitalisations, welcomes today Mithra Pharmaceuticals SA, a Belgian company focused on women’s health, on the regulated market of Euronext Brussels.

Mithra is a pharmaceutical company focused on the development, manufacturing and commercialisation of proprietary, innovative and differentiated drugs and complex generic products dedicated to female healthcare. Mithra is specialised in four different domains of Women’s Health: contraception and fertility, menopause and osteoporosis, gynecological infections and cancers.

Mithra (ticker code: MITRA)issued 6.023.809 new shares at a reference price of EUR 12 per share, giving the company an initial market capitalisation of EUR 366.5 million. The transaction raised a total of EUR 72.3 million.

François Fornieri, CEO of Mithra Pharmaceuticals, said : “It is a great honour for Mithra to inaugurate the new Euronext offices with this first IPO. For us, this is the result of four months of intensive work to reach a market capitalization of more than 366 million euros for Mithra. We have managed to raise 72,3 million euros through this IPO, an amount which will enable us to both finance research projects and to grow as a company.”

Vincent Van Dessel, CEO of Euronext Brussels, declared: “We are delighted to host such a successful company on our European market. The listing of Mithra on Europe’s leading stock exchange demonstrates the attractiveness of public equity as a source of financing the real economy and helping companies achieve their funding needs.”

Alain Baetens, Head of Listings of Euronext Brussels,added: “The IPO of Mithra was warmly welcomed by institutional and retail investors, which stresses the quality of Euronext Brussels as a major financing centre for innovative and ambitious entrepreneurs. It is the largest pharmaceutical IPO in the euro zone this year. With the support of the Enternext solutions for mid & small caps, Mithra will benefit from the access to a wide range of services that will help to raise its visibility and liquidity as a listed company.”

To celebrate the listing, François Fornieri, CEO of Mithra Pharmaceuticals, rang the bell in Brussels to open trading on Euronext’s European markets.

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €7.1 trillion in market capitalisation as of end March 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_{Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.}